Skylark Bio Advances Gene Therapy Trial for Pediatric Hearing Loss Following Safety Review

0
23
Jodi Cook, Ph.D.

CAMBRIDGE, Mass.–Skylark Bio has received a unanimous recommendation from an independent Data Safety Monitoring Board (DSMB) to expand its Phase 1/2 SONIX clinical trial of SKY-GJB2, an investigational gene therapy for children with hearing loss caused by mutations in the GJB2 gene.

The recommendation follows a review of safety data from the trial’s initial cohort of four children between the ages of 2 and 7 who received the experimental treatment.

Following the review, the DSMB recommended allowing the study to proceed to its second cohort, which will enroll younger children ranging from 9 months to less than 2 years of age.

The SONIX trial is the first clinical study evaluating a gene therapy specifically targeting GJB2-mediated hearing loss, one of the most common genetic causes of nonsyndromic deafness.

“The DSMB’s recommendation marks an important milestone for the SKY-GJB2 program and supports continued advancement of SONIX into younger children during a critical period of auditory and language development,” said Jodi Cook, Ph.D., Chief Executive Officer of Skylark Bio.

“We are encouraged by the safety profile observed to date and remain enthusiastic about the potential of SKY-GJB2 to address the underlying cause of GJB2-mediated hearing loss and transform outcomes for affected children and their families. We are grateful to the participating families, investigators, and site personnel whose partnership has made this progress possible.”

SKY-GJB2 is being developed as a one-time gene therapy designed to address the underlying genetic cause of hearing loss by delivering a functional copy of the GJB2 gene to specialized supporting cells in the cochlea.

Mutations in the GJB2 gene disrupt the function of connexin 26, a protein essential for maintaining the inner ear’s gap-junction network and normal hearing function.

The experimental therapy aims to restore this network by introducing a working copy of the gene into cells that naturally produce connexin 26.

Currently, there are no approved disease-modifying treatments for GJB2-related hearing loss. Existing interventions, including hearing aids and cochlear implants, can improve access to sound but do not correct the underlying genetic defect or restore natural hearing.

The SONIX study is a first-in-human, multicenter, open-label Phase 1/2 clinical trial enrolling children between 9 months and 7 years of age with genetically confirmed GJB2-related hearing loss.

Participants receive a single injection of SKY-GJB2 into the cochlea of one ear. Researchers are evaluating the treatment’s safety, tolerability and preliminary ability to improve hearing function.

Skylark Bio said the trial remains on schedule to generate preliminary clinical data by the end of 2026, with initial clinical results expected to be presented in 2027.

The DSMB recommendation supports continued evaluation of the experimental treatment in younger patients but does not establish its effectiveness. Additional clinical data will be needed to determine whether SKY-GJB2 can improve hearing outcomes.

Skylark Bio is a clinical-stage biotechnology company developing genetic medicines for hearing loss and other disorders caused by mutations in individual genes.

Leave A Reply

Please enter your comment!
Please enter your name here